About
Technology
- Manufacturing
- Publications
Pipeline & Clinical Trials
Patients & Families
- Epidermolysis Bullosa EB
- Localized Scleroderma
Newsroom

Contact Us

Press Releases

Proprietary Technology Platform

Dec 17, 2015

Proprietary Technology Platform

Proprietary Technology Platform

Autologous fibroblasts—the foundation for creating personalized cell and gene therapies

Recent Posts

Epidermolysis Bullosa News
Cell & Gene
Castle Creek Biosciences Announces First Patient Dosed in DeFi-RDEB Phase 3 Clinical Trial of Debcoemagene Autoficel (D-Fi) Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
Scleroderma News

Castle Creek Biosciences, Inc.
405 Eagleview Boulevard
Exton, PA 19341

Connect with us:

©2020 Castle Creek Biosciences, Inc. All Rights Reserved.
Privacy Policy | Terms of Use